The company, accelerated by Lanzadera, develops a technology based on the use of bacteriophages (also known as phages), biological entities capable of specifically attacking pathogenic bacteria. Its approach encompasses the prevention, diagnosis and treatment of bacterial infections, with applications in human, animal and plant health.
Evolving Therapeutics has raised €100k across 1 funding round from 1 investor, most recently a round in Jan 2025. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-21 | Other | €100k |
| Angels |
| View deal → |
